PCK

3.23%

3.0¢ painchek ltd

Ann: Quarterly Update and Appendix 4C, page-32

First 32 Last

Share
Profile

Follow
stockman49

657 Posts.

101

07/08/23

11:35

Post #: 69197911
Share

Just a cautionary note thats all nothings guaranteed. I am planning to ad to PCK holding as it definitely appears to be increasing its foot print. Time will tell as it will take time.

PS happily picked up more MSB at its new lows.

Originally posted by fattchoi: ↑

If I understand correctly, the problem with MSB is that their management failed to comply to the FDA wishes. FDA said you need to do this last time round. But the management thinks they know better and do it their way instead. And sure enough, FDA is now saying again, 'YOU NEED TO DO THIS!'. Hence their shareholders get bitterly disappointed.

Over here, PD and team has been in full collaboration with the FDA. This is why it is taking so long and is a slow process. At each juncture, PCK would be in touch with the FDA to ensure it is doing what the FDA required and adjust if required. And so far, it is progressing nicely, as is prescribed by the FDA. The FDA will get what the FDA wants. Anything else, and you are running the risk of them saying NO outright. All these collaboration coupled with real life application out there in reputable countries like Australia, England, NZ, Singapore, etc will put weight in the FDA decision making here. Nothing is a guarantee but this is as good as a sure thing already.

You are spot on there. Just the aged care sector will ensure PCK will reach that revenue neutral status and more. Everything else like the children, hospital, pharmacy, homecare, etc sector, are all going straight into the bottom line. Just a matter of time when anyone who holds shares at today's price are going to be free carried when the dividend starts flowing. And that is ignoring what the capital gains would be by then!

Expand

PCK Price at posting: 2.8¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 10 more messages in this thread...

First 32 Last

Add PCK (ASX) to my watchlist

(20min delay)
Last 3.0¢		Change -0.001(3.23%)		Mkt cap ! $49.11M

Open	High	Low	Value	Volume
3.0¢	3.0¢	3.0¢	$12.08K	402.6K

Buyers (Bids)

No.	Vol.	Price($)
8	305189	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.1¢	99999	1

View Market Depth

No.	Vol.	Price($)
7	288356	0.030
5	6607448	0.029
1	350000	0.028
3	488344	0.027
4	1600000	0.026

Price($)	Vol.	No.
0.031	99999	1
0.032	102605	2
0.033	126161	2
0.034	79638	2
0.035	125000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PCK (ASX) Chart

Ann: Quarterly Update and Appendix 4C, page-32

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Update and Appendix 4C, page-32

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News